文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

一种基于铁蛋白的 COVID-19 纳米颗粒疫苗，在非人类灵长类动物中引发了强大、持久、广谱的中和抗体血清。

A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates.

机构信息

Sarafan ChEM-H, Stanford University, Stanford, CA, USA.

Department of Chemistry, Stanford University, Stanford, CA, USA.

出版信息

Nat Commun. 2023 Apr 17;14(1):2149. doi: 10.1038/s41467-023-37417-9.

DOI:10.1038/s41467-023-37417-9
PMID:37069151
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10110616/
Abstract

While the rapid development of COVID-19 vaccines has been a scientific triumph, the need remains for a globally available vaccine that provides longer-lasting immunity against present and future SARS-CoV-2 variants of concern (VOCs). Here, we describe DCFHP, a ferritin-based, protein-nanoparticle vaccine candidate that, when formulated with aluminum hydroxide as the sole adjuvant (DCFHP-alum), elicits potent and durable neutralizing antisera in non-human primates against known VOCs, including Omicron BQ.1, as well as against SARS-CoV-1. Following a booster ~one year after the initial immunization, DCFHP-alum elicits a robust anamnestic response. To enable global accessibility, we generated a cell line that can enable production of thousands of vaccine doses per liter of cell culture and show that DCFHP-alum maintains potency for at least 14 days at temperatures exceeding standard room temperature. DCFHP-alum has potential as a once-yearly (or less frequent) booster vaccine, and as a primary vaccine for pediatric use including in infants.

摘要

虽然 COVID-19 疫苗的快速发展是一项科学上的胜利，但仍需要一种全球可获得的疫苗，以提供针对当前和未来 SARS-CoV-2 关注变体（VOCs）的更持久免疫力。在这里，我们描述了 DCFHP，一种基于铁蛋白的蛋白质纳米颗粒疫苗候选物，当与作为唯一佐剂的氢氧化铝（DCFHP-alum）联合使用时，在非人类灵长类动物中引发针对已知 VOCs 的强大且持久的中和抗体，包括奥密克戎 BQ.1 以及 SARS-CoV-1。在初始免疫后约一年进行加强针接种后，DCFHP-alum 引发了强烈的回忆反应。为了实现全球可及性，我们生成了一种能够使每升细胞培养物生产数千剂疫苗的细胞系，并表明 DCFHP-alum 在标准室温以上至少 14 天内保持效力。DCFHP-alum 具有作为每年一次（或更频繁）加强针疫苗的潜力，也可作为儿科使用的主要疫苗，包括婴儿。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85d5/10110616/79102452dadb/41467_2023_37417_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85d5/10110616/5e2f55cff5cb/41467_2023_37417_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85d5/10110616/306b84d5087e/41467_2023_37417_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85d5/10110616/89e9ec7eac0d/41467_2023_37417_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85d5/10110616/17866d10726f/41467_2023_37417_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85d5/10110616/a55e9de8de75/41467_2023_37417_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85d5/10110616/79102452dadb/41467_2023_37417_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85d5/10110616/5e2f55cff5cb/41467_2023_37417_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85d5/10110616/306b84d5087e/41467_2023_37417_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85d5/10110616/89e9ec7eac0d/41467_2023_37417_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85d5/10110616/17866d10726f/41467_2023_37417_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85d5/10110616/a55e9de8de75/41467_2023_37417_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85d5/10110616/79102452dadb/41467_2023_37417_Fig6_HTML.jpg

相似文献

[1]
A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates.

Nat Commun. 2023-4-17

[2]
A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates.

bioRxiv. 2022-12-26

[3]
Formulation development and comparability studies with an aluminum-salt adjuvanted SARS-CoV-2 spike ferritin nanoparticle vaccine antigen produced from two different cell lines.

Vaccine. 2023-10-20

[4]
Beta variant COVID-19 protein booster vaccine elicits durable cross-neutralization against SARS-CoV-2 variants in non-human primates.

Nat Commun. 2023-3-10

[5]
A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates.

Sci Transl Med. 2022-2-16

[6]
Decreased efficacy of a COVID-19 vaccine due to mutations present in early SARS-CoV-2 variants of concern.

bioRxiv. 2023-6-29

[7]
Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.

J Infect. 2023-9

[8]
A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.

Elife. 2022-8-25

[9]
Self-assembled ferritin-based nanoparticles elicit a robust broad-spectrum protective immune response against SARS-CoV-2 variants.

Int J Biol Macromol. 2024-4

[10]
A receptor-binding domain-based nanoparticle vaccine elicits durable neutralizing antibody responses against SARS-CoV-2 and variants of concern.

Emerg Microbes Infect. 2023-12

引用本文的文献

[1]
Baculovirus-mediated production and purification of ferritin nanoparticles for rift valley fever vaccine development.

J Biol Eng. 2025-8-14

[2]
Development of a Ferritin-Based Nano-Allergen and Its Immunological Effects in vitro and in vivo.

Int J Nanomedicine. 2025-7-30

[3]
A two-component cocktail of engineered DIII nanoparticles elicits broadly neutralizing antibody responses against dengue virus in mice.

iScience. 2025-4-29

[4]
Progress and Challenges in HIV-1 Vaccine Research: A Comprehensive Overview.

Vaccines (Basel). 2025-1-31

[5]
A SARS-CoV-2 vaccine on an NIR-II/SWIR emitting nanoparticle platform.

Sci Adv. 2025-2-7

[6]
Optimization of Conditions for Expression of Dengue Serotype 2 EDIII Protein in and Immune Responses of Adjuvant-Free EDIII Ferritin Nanoparticles Against Dengue Virus in BALB/c Mice.

Viruses. 2025-1-17

[7]
Designed mosaic nanoparticles enhance cross-reactive immune responses in mice.

Cell. 2025-2-20

[8]
Screened Fv-Antibodies against the Angiotensin-Converting Enzyme 2 (ACE2) Receptor Neutralizing the Infection of SARS-CoV-2.

ACS Pharmacol Transl Sci. 2024-11-19

[9]
Protein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV.

Cell Rep. 2024-12-24

[10]
Challenges in Exploiting Human H Ferritin Nanoparticles for Drug Delivery: Navigating Physiological Constraints.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024

本文引用的文献

[1]
Formulation development and comparability studies with an aluminum-salt adjuvanted SARS-CoV-2 spike ferritin nanoparticle vaccine antigen produced from two different cell lines.

Vaccine. 2023-10-20

[2]
Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers.

Sci Transl Med. 2023-3-22

[3]
A Covid-19 Milestone Attained - A Correlate of Protection for Vaccines.

N Engl J Med. 2022-12-15

[4]
Urgent Need for Next-Generation COVID-19 Vaccines.

JAMA. 2023-1-3

[5]
Simplified Purification of Glycoprotein-Modified Ferritin Nanoparticles for Vaccine Development.

Biochemistry. 2023-1-17

[6]
Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum.

Cell. 2022-7-7

[7]
Global impact of the first year of COVID-19 vaccination: a mathematical modelling study.

Lancet Infect Dis. 2022-9

[8]
Correlates of protection against SARS-CoV-2 infection and COVID-19 disease.

Immunol Rev. 2022-9

[9]
Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity.

Cell. 2022-4-28

[10]
Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination.

Cell. 2022-3-17

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索